A phase 3 clinical study of rituximab (Rituxan) for the treatment of rheumatoid arthritis (RA) showed that patients who received 2 infusions of rituximab along with a stable dose of methotrexate experienced a 20%, 50%, and 70% improvement in the number of swollen and tender joints, as compared with a placebo. These percentages correspond to a standard assessment used by the American College of Rheumatology (ACR) that measures patients' responses to antirheumatic therapies. The 24-week, multicenter, double-blind, placebo-controlled study included 520 patients with active RA who had not responded well to prior treatment with >1 anti-tumor necrosis factor (TNF) therapies. Among those who received rituximab, 51% achieved ACR 20, compared with 18% of placebo patients; 27% achieved ACR 50, compared with 5% in the placebo group; and 12% achieved ACR 70, compared with 1% in the placebo group. The incidence of serious infections was low in both the rituximab and the placebo groups2% and 1%, respectively. Clinicians are encouraged by this trial, because few options currently exist for RA patients who do not respond to anti-TNF therapy.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs